Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant lenvatinib plus camrelizumab for resectable hepatocellular carcinoma at high risk of recurrence
ChiCTR2300071610Phase 4Not yet recruiting
- Sponsor
- Mengchao Hepatobiliary Hospital of Fujian Medical University
- Start
- May 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of lenvatinib and camrelizumab in hepatocellular carcinoma (HCC), sponsored by Mengchao Hepatobiliary Hospital of Fujian Medical University. Primary endpoints: R0 resection rate, Relapse-free survival and 2 more. Planned start May 2023; status: not yet recruiting.
02
Drugs
lenvatinibcamrelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2300071610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300071610.